This is a routine Form 144 filing by a director. The sale amount is small relative to Gilead's market cap. No material impact expected. Monitor for any subsequent Form 4 filings to confirm execution.
GILD drugs
GILD drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $168.08entry
- T+1 · 15h ago −0.30%α +1.61% · $167.58
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Kelly Kramer filed a Form 144 notice of intent to sell 10,376 shares of Gilead Sciences common stock, with an estimated aggregate market value of approximately $1.76 million. The shares were acquired through exercise of stock options on the same day as the filing. The sale represents a routine insider transaction by a director and is not material relative to Gilead's market cap.
Key Facts
- Reporting person: Kelly A. Kramer, Director of Gilead Sciences
- Proposed sale of 10,376 shares of common stock
- Estimated aggregate market value: $1,761,118.48
- Shares acquired via exercise of stock options on 2026-11-12
- Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
- Sale intended to be executed on NASDAQ
Financial Impact
Approximately $1.76 million, representing a small fraction of the director's holdings and a negligible percentage of Gilead's market cap.
Risk Factors
- Insider selling could be perceived negatively if it precedes negative news, but no such context is present here.
- The sale may not occur; Form 144 is an intent to sell.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-011039 |
| Document: 0001950047-26-011039-index.html | 0001950047-26-011039 |
| Document: 0001950047-26-011039.txt | 0001950047-26-011039 |
Track record
30 reports on GILD
5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +22.38% at T+60 after the Aug 13, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $167.58 Now $167.58 +0.00% settles Feb 16
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $167.71 Now $167.58 −0.08% settles Feb 12
- Nov 13, 20264d ago Court Ruling Bullish 4/10 Entry $170.99 Now $167.58 −1.99% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Viewing Entry $168.08 Now $167.58 −0.30% settles Feb 11
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $170.87 Now $167.58 −1.93% settles Feb 8
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $169.32 Now $167.58 −1.03% settles Feb 5
- Nov 4, 202612d ago 144 Neutral 3/10 Entry $167.57 Now $167.58 +0.01% settles Feb 3
- Oct 30, 202617d ago 144 Neutral 3/10 Entry $170.33 Now $167.58 −1.61% settles Jan 29
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $170.68 Now $167.58 −1.82% settles Jan 28
- Oct 22, 202625d ago Institutional Cluster Bearish 4/10 Entry $156.04 Now $167.58 −7.40% settles Jan 21
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers